For all intents and purposes YES. INLS, IMO, has to know the results. News when we get it (someday) will be all inclusive.
#2 TauC3; "test the therapeutic and prophylactic potential of TauC3" Dr. LaFerla's group at UCI completed the animal testing and currently is accumulating the data and preparing a report describing the results of the experiments"
"Intellect Neurosciences. The company has a market valuation of only $1.5 million. But Mr. Blech said that if a drug for Alzheimer’s disease showed some promise in animal testing, Intellect could be acquired for a much larger sum."
ABOUT TauC3; TauC3 Alzheimer's drug candidate Intellect's exclusive license from Northwestern University to TauC3 for all therapeutic and diagnostic applications remains in full force and effect. TauC3 is a high affinity IgG monoclonal antibody that uniquely binds to Asp421 at the C-terminus of ?tau, believed to be an important mediator in tau pathology. Intellect is collaborating with Dr. Frank LaFerla at University of California Irvine to test the therapeutic and prophylactic potential of TauC3 in a triple transgenic mouse model of Alzheimer's disease that exhibits both Aß and Tau pathologies. Recently, Dr. LaFerla's group at UCI completed the animal testing and currently is accumulating the data and preparing a report describing the results of the experiments. We intend to share those results with you promptly upon receipt. Several pharmaceutical companies have expressed interest in our TauC3 program as it represents a first in class and novel alternative therapeutic treatment for AD.
News 
Market Data 
Discover 
